Le Lézard
Classified in: Health
Subjects: SVY, FDA

SSQ Insurance adds pharmacogenetic testing to its group insurance offering


QUEBEC CITY, Oct. 1, 2019 /CNW Telbec/ - SSQ Insurance now offers coverage of pharmacogenetic tests as a new option in group insurance. These tests help analyze how a person's DNA will react to a prescription drug, making it easier for attending physicians to identify the most appropriate drug for each patient. SSQ Insurance aims to make life easier for its insured customers by helping them access optimal treatment, and for its policyholders by making it possible to better control the cost of drugs. 

"Since the treatment of disease is evolving toward personalized solutions for individual patients, pharamacogenetics is quickly becoming a must. We wanted to develop a product adapted to this reality and make it available to our customers across Canada. SSQ Insurance is the first insurer to expand its health insurance offering by adding a clause for pharmacogenetic tests that is separate from the traditional clause for laboratory analyses. In doing so, we demonstrate our proactivity in bringing technological advances in health to our customers," said Éric Trudel, Senior Vice-President of Strategy and Product Management at SSQ Insurance.

At the policyholder's request and in accordance with a reimbursement maximum they will choose, the new clause may be added to their health insurance coverage. To be eligible, pharmacogenetic testing must be prescribed by a physician and carried out in a duly authorized laboratory in Canada. The results of genetic tests are used to identify the most appropriate drugs for the treatment of such conditions as attention deficit disorder (ADD), psychological illnesses, and chronic diseases like hypertension and chronic pain. The results of genetic tests are never provided to the insurer. In fact, any genetic information is excluded when the physician transfers a medical file to the insurer, thus respecting the confidential nature of this information.

The addition of this new clause in health insurance is being made in parallel to a pilot project in disability insurance launched in June 2018. As part of the project, pharmacogenetic testing is offered to insured persons on disability leave who have been diagnosed with depression. The technological advances and the success of the pilot project have allowed SSQ Insurance to develop the new clause now available in group health insurance.

About SSQ Insurance
Founded in 1944, SSQ Insurance is a mutualist company that puts community at the heart of insurance. With assets under management of $12 billion, SSQ Insurance is one of the largest companies in the industry. Working for a community of over three million customers, SSQ Insurance employs over 2,000 people. Leader in group insurance, the company also sets itself apart through its expertise in individual life and health insurance, general insurance and the investment sector. For more information, please visit ssq.ca.

SOURCE SSQ Insurance


These press releases may also interest you

at 13:14
The Hermes Creative Awards, one of the world's largest competitions honoring the messengers and creators of traditional and emerging media, has awarded PatientPoint® content with 14 Hermes Platinum and Gold awards for outstanding creative....

at 13:14
Sixteen finalists are announced in the "Make Your Medical Device Pitch for Kids!" special COVID-19 edition competition presented by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). Representing innovations in...

at 13:10
The team at Smiles by Hogan encourages patients with symptoms of gingivitis to seek LANAP® gum disease treatment to boost their oral health and immune system amid the COVID-19 pandemic. Dr. Kevin Hogan, founding dentist of Smiles by Hogan in Mt....

at 13:07
The Florida Blue Foundation has recognized individuals, programs and organizations that are addressing issues of poverty and opioids/substance abuse with its annual Sapphire Award for excellence and innovation in community health. Those recognized...

at 13:06
Spherix recently fielded a survey of 152 hematologists/oncologists in the US in order to assess the current and future treatment paradigms of anemia patients treated by this specialist population. According to the Market Dynamixtm survey,  anemia is...

at 13:05
Today Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, announces a transition in leadership to fulfill the potential of the INNOVO® brand in the large and under-served US Stress Urinary Incontinence market. Atlantic...



News published on 1 october 2019 at 08:30 and distributed by: